Castle Biosciences, Inc. (NASDAQ:CSTL – Get Free Report) COO Kristen Oelschlager sold 8,586 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The shares were sold at an average price of $24.42, for a total transaction of $209,670.12. Following the sale, the chief operating officer directly owned 21,874 shares of the company’s stock, valued at approximately $534,163.08. This represents a 28.19% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Castle Biosciences Trading Down 0.8%
Shares of Castle Biosciences stock opened at $23.64 on Thursday. Castle Biosciences, Inc. has a 1-year low of $14.59 and a 1-year high of $44.28. The company’s fifty day simple moving average is $21.51 and its 200-day simple moving average is $28.24. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.75 and a quick ratio of 6.53. The stock has a market capitalization of $717.00 million, a PE ratio of -53.73 and a beta of 1.00.
Castle Biosciences (NASDAQ:CSTL – Get Free Report) last announced its earnings results on Wednesday, May 6th. The company reported ($0.49) EPS for the quarter, hitting analysts’ consensus estimates of ($0.49). The company had revenue of $84.23 million for the quarter, compared to analysts’ expectations of $79.23 million. Castle Biosciences had a negative return on equity of 2.77% and a negative net margin of 3.78%. As a group, equities analysts anticipate that Castle Biosciences, Inc. will post -1.56 earnings per share for the current year.
Wall Street Analysts Forecast Growth
Check Out Our Latest Stock Report on Castle Biosciences
Hedge Funds Weigh In On Castle Biosciences
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Federated Hermes Inc. purchased a new stake in Castle Biosciences during the 4th quarter valued at $26,000. Kemnay Advisory Services Inc. purchased a new position in Castle Biosciences during the fourth quarter worth $35,000. Jones Financial Companies Lllp increased its position in Castle Biosciences by 10,592.0% during the first quarter. Jones Financial Companies Lllp now owns 2,673 shares of the company’s stock valued at $54,000 after acquiring an additional 2,648 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its position in Castle Biosciences by 26.5% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,418 shares of the company’s stock valued at $55,000 after acquiring an additional 297 shares during the last quarter. Finally, Russell Investments Group Ltd. raised its stake in shares of Castle Biosciences by 63.7% in the third quarter. Russell Investments Group Ltd. now owns 2,508 shares of the company’s stock valued at $57,000 after acquiring an additional 976 shares during the period. 92.60% of the stock is owned by hedge funds and other institutional investors.
About Castle Biosciences
Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.
The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.
Featured Articles
- Five stocks we like better than Castle Biosciences
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Castle Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Castle Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
